drugset / Trial / NCT04439721
γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse
Phase 0
Unknown
5 enrolled
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First Affiliated Hospital of Soochow University · collab
NaSingle-groupOpen-labelPrevention
Summary
Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Timeline
- Start
- 2020-05-01
- Primary completion
- 2021-05-01
- Completion
- 2021-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | γδ T cells | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | γδ T cells | Cell therapy | 8e+07 cells/kg | Intravenous |